Research Analysts Issue Forecasts for TPST FY2028 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Analysts at William Blair issued their FY2028 EPS estimates for Tempest Therapeutics in a research note issued to investors on Thursday, March 27th. William Blair analyst M. Phipps anticipates that the company will earn ($1.60) per share for the year. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The company had revenue of $0.49 million for the quarter.

A number of other equities analysts have also recently weighed in on TPST. HC Wainwright decreased their price target on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating for the company in a report on Friday, March 28th. Scotiabank decreased their target price on shares of Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a research note on Friday, March 28th.

Tempest Therapeutics Price Performance

Shares of NASDAQ TPST opened at $0.71 on Monday. Tempest Therapeutics has a 1-year low of $0.70 and a 1-year high of $6.00. The company has a market capitalization of $31.19 million, a price-to-earnings ratio of -0.47 and a beta of -1.83. The business has a 50-day moving average of $0.86 and a 200-day moving average of $0.97.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of Tempest Therapeutics in the 3rd quarter valued at approximately $34,000. Virtu Financial LLC bought a new stake in shares of Tempest Therapeutics in the fourth quarter worth $36,000. Northern Trust Corp raised its holdings in Tempest Therapeutics by 233.2% in the fourth quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock valued at $57,000 after acquiring an additional 47,461 shares in the last quarter. Millennium Management LLC acquired a new position in Tempest Therapeutics during the 4th quarter worth $158,000. Finally, Geode Capital Management LLC grew its holdings in Tempest Therapeutics by 61.0% during the 4th quarter. Geode Capital Management LLC now owns 354,276 shares of the company’s stock worth $296,000 after acquiring an additional 134,209 shares in the last quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.